Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 18
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Comorbidities, medication use, and overall survival in eight cancers, a multinational cohort study of 1.7 million patients across Europe

  • López-Sánchez, Irene
  • Palomar-Cros, Anna|||0000-0001-8151-9290
  • Claire, Ravinder|||0000-0001-8039-6161
  • Pérez-Crespo, Laura|||0000-0002-8288-5716
  • Giuliodori, Agustina
  • Koblbauer, Ian
  • Dietz, Jeremy
  • Elvidge, Jamie
  • Koh, James
  • Golozar, Asieh|||0000-0002-4243-155X
  • Ramírez-Anguita, Juan Manuel|||0000-0002-8509-0927
  • Leis, Angela
  • Mayer, Miguel Angel|||0000-0003-0362-6298
  • Symmers, Nicola
  • Vallet, Mahéva|||0000-0001-7007-0782
  • McLean, Colin|||0000-0002-8937-0619
  • Hall, Peter S.|||0000-0001-6015-7841
  • Mosseveld, Mees|||0000-0001-9301-8565
  • Verhamme, Katia|||0000-0001-8162-4904
  • Enerly, Espen|||0000-0002-2974-2273
  • Prinsen, Peter|||0000-0002-0444-4579
  • Evers, Jelle
  • Oja, Marek
  • Kolde, Raivo
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
  • Fey, Eric
  • Porkka, Kimmo|||0000-0003-4112-5902
  • Taveira-Gomes, Tiago
  • Estevinho, Fernanda
  • Moreno Conde, Alberto
  • Moreno Conde, Jesus
  • Miguez Sanchez, Carlos
  • Fournier, Evelyne
  • Pistillo, Andrea|||0000-0002-4467-0220
  • Chen, Xihang
  • Corby, George|||0000-0002-5057-2985
  • Robinson, Abigail
  • Sanchez-Santos, Maria T.
  • Delmestri, Antonella|||0000-0003-0388-3403
  • Man, Wai Yi
  • Català, Martí|||0000-0003-3308-9905
  • Alcalde-Herraiz, Marta
  • Burn, Edward|||0000-0002-9286-1128
  • Prieto-Alhambra, Daniel|||0000-0002-3950-6346
  • Duarte Salles, Talita|||0000-0002-8274-0357
  • Newby, Danielle|||0000-0002-3001-1478
Background: Real-world evidence provides valuable insights into cancer burden, presentation, and care variations. Through a large-scale federated approach, this study aims to explore patient characteristics and overall survival for eight cancers using data from 11 electronic health records and cancer registries from eight European countries, mapped to the Observational Medical Outcomes Partnership Common Data Model (OMOP-CDM). Methods: Patients aged 18 years or older with a primary cancer diagnosis between 2000 and 2019 were included. Patients were followed from cancer diagnosis until death, database exit, or study end. Mortality data was sourced from linked national or subnational death registries for most databases. Patient characteristics, including comorbidities, and medication use, were summarised. Age-standardised overall survival (OS) at one, five, and ten years were calculated using the Kaplan-Meier method and stratified by cancer type, age group and sex. Findings: There were 1,796,278 eligible cancer patients included with most diagnoses in individuals aged 60-79 years. Top comorbidities and medications were relatively consistent across databases, with certain variations observed by cancer type, possibly indicative of early cancer signs and risk factors. For instance, anaemia was frequent in colorectal (9% [HUS]-23% [IMASIS]; 791/8395-730/3141 individuals) and stomach cancers (10% [HUS]-34% [IMASIS]; 130/1277-225/670), while chronic obstructive pulmonary disease (18% [SIDIAP]-34% [HUVM], 5310/29,009-1039/3063) and pneumonia (5% [CPRD GOLD]-33% [UTARTU], 1904/34,990-1001/3063) were common in lung cancer patients. Breast and prostate cancers had the highest one, five and ten-year overall survival, with 5-year OS ranging from 76% [ECi]-85% [IMASIS] and 75% [HUVM]-83% [SIDIAP], respectively. Pancreatic cancer showed the lowest survival ranging from 3% [NCR]-25% [IMASIS] 5-year OS. Variations in cancer survival estimates were observed across data sources and countries. Interpretation: Federated analysis of diverse European real-world databases, standardised to OMOP-CDM, offer a valuable benchmark for future cancer research, particularly in understanding prodromes and risk factors, often recorded in routinely collected healthcare data prior to cancer onset. Funding: The European Health Data & Evidence Network has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations partners.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Incidence and Survival of Colorectal Cancer in the United Kingdom From 2000 to 2021, A Population-Based Cohort Study

  • Pedregal-Pascual, Patricia|||0000-0002-0321-9927
  • Guarner-Argente, Carlos|||0000-0002-8180-1488
  • Tan, Eng Hooi
  • Golozar, Asieh|||0000-0002-4243-155X
  • Duarte Salles, Talita|||0000-0002-8274-0357
  • Rosen, Andreas Weinberger|||0000-0001-9990-8155
  • Delmestri, Antonella|||0000-0003-0388-3403
  • Man, Wai Yi
  • Burn, Edward|||0000-0002-9286-1128
  • Prieto-Alhambra, Daniel|||0000-0002-3950-6346
  • Newby, Danielle|||0000-0002-3001-1478
The management of colorectal cancer (CRC) is evolving, with advances in screening and treatment. The purpose of this study was to leverage population-based data to generate up-to-date UK estimates of age-specific and sex-specific incidence and overall survival for the period 2000-2021. We analyzed nationally representative primary care records from Clinical Practice Research Datalink GOLD and replicated in Clinical Practice Research Datalink Aurum. We calculated incidence rates, and short-term and long-term survival stratified by age, sex, and diagnosis year. Overall incidence was 67.4/100,000 person years, increasing in 2000-2011 to drop slightly in 2011-2014, and then plateauing. By contrast, early-onset CRC raised uninterruptedly throughout the study period, from 8.33 to 19.07/100,000 person-years. Overall survival was 78.3%, 51.4%, and 38.5% at 1, 5, and 10 years, respectively, lower in men compared with women. Modest improvements in survival were observed over the study period, particularly for 60-69-year-old patients. Although the overall incidence in the population has plateaued, a worrying increasing trend of early-onset CRC was observed. Moreover, the slight improvement in overall survival suggests that significant progress is still needed. These findings highlight the urgent need for continued research and resource allocation to improve the diagnosis and management of CRC.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Phenotype algorithms for the identification and characterization of vaccine-induced thrombotic thrombocytopenia in real world data: a multinational network cohort study

  • Shoaibi, Azza
  • Mayer, Miguel Ángel, 1960-
  • Ramírez Anguita, Juan Manuel
  • Ryan, Patrick B.
Introduction: vaccine-induced thrombotic thrombocytopenia (VITT) has been identified as a rare but serious adverse event associated with coronavirus disease 2019 (COVID-19) vaccines. Objectives: in this study, we explored the pre-pandemic co-occurrence of thrombosis with thrombocytopenia (TWT) using 17 observational health data sources across the world. We applied multiple TWT definitions, estimated the background rate of TWT, characterized TWT patients, and explored the makeup of thrombosis types among TWT patients. Methods: we conducted an international network retrospective cohort study using electronic health records and insurance claims data, estimating background rates of TWT amongst persons observed from 2017 to 2019. Following the principles of existing VITT clinical definitions, TWT was defined as patients with a diagnosis of embolic or thrombotic arterial or venous events and a diagnosis or measurement of thrombocytopenia within 7 days. Six TWT phenotypes were considered, which varied in the approach taken in defining thrombosis and thrombocytopenia in real world data. Results: overall TWT incidence rates ranged from 1.62 to 150.65 per 100,000 person-years. Substantial heterogeneity exists across data sources and by age, sex, and alternative TWT phenotypes. TWT patients were likely to be men of older age with various comorbidities. Among the thrombosis types, arterial thrombotic events were the most common. Conclusion: our findings suggest that identifying VITT in observational data presents a substantial challenge, as implementing VITT case definitions based on the co-occurrence of TWT results in large and heterogeneous incidence rate and in a cohort of patints with baseline characteristics that are inconsistent with the VITT cases reported to date., This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA. Funders had no role in the conceptualization, design, data collection, analysis, decision to publish, or preparation of the manuscript.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Incidence of post-acute COVID-19 symptoms across healthcare settings in seven countries: an international retrospective cohort study using routinely-collected data

  • Xie, Junqing
  • Mayer, Miguel Ángel, 1960-
  • Ramírez Anguita, Juan Manuel
  • Jödicke, Annika M.
Background: The World Health Organisation (WHO) has identified a range of symptomatic manifestations to aid in the clinical diagnosis of post-COVID conditions, herein referred to as post-acute COVID-19 symptoms. We conducted an international network cohort study to estimate the burden of these symptoms in North American, European, and Asian populations. Methods: A federated analysis was conducted including 10 databases from the United Kingdom, Netherlands, Norway, Estonia, Spain, France, South Korea, and the United States, between September 1st 2020 and latest data availability (which varied from December 31st 2021 to February 28th 2023), covering primary and secondary care, nationwide registries, and claims data, all mapped to the Observational Medical Outcomes Partnership Common Data Model (OMOP CDM). We defined two cohorts for the main analyses: a SARS-CoV-2 infection cohort [positive polymerase chain reaction (PCR) or rapid lateral flow test (LFT) result or clinical COVID-19 diagnosis] and a general population cohort. Individuals with less than 365 days of prior history or 120 days of follow-up were excluded. We estimated incidence rates (IRs) of the 25 WHO-proposed post-acute COVID-19 symptoms, considering symptoms that occurred ≥90 and ≤365 days after index date, excluding individuals with the respective symptoms 180 days prior to the index event. Stratified analyses were conducted by age and sex. Incidence rate ratios (IRRs) were calculated comparing rates in the infected cohort versus the general population. Results from the different databases were combined using random-effects meta-analyses. Findings: 3,019,408 individuals were included in the infection cohort. 1,585,160 of them were female and 1,434,248 of them male. 929,351,505 individuals were included in the general population group. 461,195,036 of them were female and 466,022,004 of them male. The 1-year IR of any post-acute COVID-19 symptom in the COVID-19 infection cohort varied significantly across databases, from 4.4 (95% CI 3.8-5.1) per 100 person-years to 103.9 (95% CI 103.2-104.7). The five most common symptoms were joint pain (from 1.6 (95% CI 1.3-1.9) to 14.3 (95% CI 14.1-14.6)), abdominal pain (from 0.3 (95% CI 0.1-0.5) to 9.9 (95% CI 9.7-10.1)), gastrointestinal issues (from 0.6 (95% CI 0.4-0.9) to 13.3 (95% CI 13.1-13.6)), cough (from 0.3 (95% CI 0.2-0.5) to 9.1 (95% CI 8.9-9.3)), and anxiety (from 0.8 (95% CI 0.6-1.2) to 11.4 (95% CI 11.2-11.6)); whereas muscle spasms (from 0.01 (95% CI 0.008-0.2) to 1.7 (95% CI 1.6-1.8)), pins and needles (from 0.05 (95% CI 0.03-0.0.9) to 1.5 (95% CI 1.4-1.6)), memory issues (from 0.03 (95% CI 0.02-0.06) to 0.8 (95% CI 0.7-0.8)), cognitive dysfunction (from 0.007 (95% CI 0.004-0.01) to 0.6 (95% CI 0.4-0.8)), and altered smell and/or taste (from 0.04 (95% CI 0.03-0.04) to 0.7 (95% CI 0.6-0.8)) were least common. Incidence rates of any post-acute COVID-19 symptoms generally increased with age, with certain symptoms peaking in middle-aged adults (anxiety, depressive disorders, headache, altered smell and taste) and others in pre-school children (gastrointestinal issues and cough). Females had higher incidence rates for most symptoms. Based on the random-effects model, the infected cohort had a higher incidence of any post-acute COVID-19 symptom than the general population, with a meta-analytic incidence rate ratio (meta-IRR) of 1.4 (1-2). A similar pattern was seen for all individual symptoms. The highest meta-IRRs were depressive disorder, 2.6 (1.7-3.9); anxiety, 2.3 (1.4-3.8); allergy, 2.1 (1.7-2.8) and sleep disorders, 2.1 (1.5-2.6). The meta-IRR for altered smell and/or taste was 1.9 (1.3-2.8). Interpretation: Post-acute COVID-19 symptoms, as listed by the WHO, were commonly observed following COVID-19 infection. However, even after standardising research methods, there was significant heterogeneity in the incidence rates from different healthcare settings and geographical locations. This is the first international study of the epidemiology of post-acute COVID-19 symptoms using the WHO-listed symptoms. Its findings contibute to understand the epidemiology of this condition from a multinational approach. Limitations of this study include the lack of consensus of the post-acute COVID-19 definition, as well as the difficulty to capture the impact on daily life of the post-acute COVID-19 symptoms in the available datasets. Funding: This work has been funded by the European Health Data Evidence Network (EHDEN) through an Evidence Generation Fund Grant and by the National Institute for Health and Care Research (NIHR) Oxford Biomedical Research Centre (BRC)., This work has been funded by the European Health Data Evidence Network (EHDEN) through an Evidence Generation Fund Grant. EHDEN has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 806968. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Evaluating the impact of alternative phenotype definitions on incidence rates across a global data network

  • Makadia, Rupa
  • Shoaibi, Azza
  • Rao, Gowtham A.
  • Ostropolets, Anna
  • Rijnbeek, Peter
  • Voss, Erica A.
  • Duarte Salles, Talita, 1985-
  • Ramírez Anguita, Juan Manuel
  • Mayer, Miguel Ángel, 1960-
  • Maljkovic, Filip
  • Denaxas, Spiros
  • Nyberg, Fredrik
  • Papez, Vaclav
  • Sena, Anthony G.
  • Alshammari, Thamir M.
  • Lai, Lana Y. H.
  • Haynes, Kevin
  • Suchard, Marc A.
  • Hripcsak, George
  • Ryan, Patrick B.
Objective: Developing accurate phenotype definitions is critical in obtaining reliable and reproducible background rates in safety research. This study aims to illustrate the differences in background incidence rates by comparing definitions for a given outcome. Materials and methods: We used 16 data sources to systematically generate and evaluate outcomes for 13 adverse events and their overall background rates. We examined the effect of different modifications (inpatient setting, standardization of code set, and code set changes) to the computable phenotype on background incidence rates. Results: Rate ratios (RRs) of the incidence rates from each computable phenotype definition varied across outcomes, with inpatient restriction showing the highest variation from 1 to 11.93. Standardization of code set RRs ranges from 1 to 1.64, and code set changes range from 1 to 2.52. Discussion: The modification that has the highest impact is requiring inpatient place of service, leading to at least a 2-fold higher incidence rate in the base definition. Standardization showed almost no change when using source code variations. The strength of the effect in the inpatient restriction is highly dependent on the outcome. Changing definitions from broad to narrow showed the most variability by age/gender/database across phenotypes and less than a 2-fold increase in rate compared to the base definition. Conclusion: Characterization of outcomes across a network of databases yields insights into sensitivity and specificity trade-offs when definitions are altered. Outcomes should be thoroughly evaluated prior to use for background rates for their plausibility for use across a global network., This research was funded by the European Union’s Horizon 2020 research and innovation programme and EFPIA, European Health Data & Evidence Network (EHDEN) grant agreement number 806968. T.D.-S. acknowledges receiving financial support from the Instituto de Salud Carlos III (ISCIII; Miguel Servet 2021: CP21/00023).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Characteristics and outcomes of patients with COVID-19 with and without prevalent hypertension: a multinational cohort study

  • Reyes, Carlen
  • Sorli Redó, M. Luisa
  • López Montesinos, Inmaculada
  • Duarte Salles, Talita, 1985-
Objective: To characterise patients with and without prevalent hypertension and COVID-19 and to assess adverse outcomes in both inpatients and outpatients. Design and setting: This is a retrospective cohort study using 15 healthcare databases (primary and secondary electronic healthcare records, insurance and national claims data) from the USA, Europe and South Korea, standardised to the Observational Medical Outcomes Partnership common data model. Data were gathered from 1 March to 31 October 2020. Participants: Two non-mutually exclusive cohorts were defined: (1) individuals diagnosed with COVID-19 (diagnosed cohort) and (2) individuals hospitalised with COVID-19 (hospitalised cohort), and stratified by hypertension status. Follow-up was from COVID-19 diagnosis/hospitalisation to death, end of the study period or 30 days. Outcomes: Demographics, comorbidities and 30-day outcomes (hospitalisation and death for the 'diagnosed' cohort and adverse events and death for the 'hospitalised' cohort) were reported. Results: We identified 2 851 035 diagnosed and 563 708 hospitalised patients with COVID-19. Hypertension was more prevalent in the latter (ranging across databases from 17.4% (95% CI 17.2 to 17.6) to 61.4% (95% CI 61.0 to 61.8) and from 25.6% (95% CI 24.6 to 26.6) to 85.9% (95% CI 85.2 to 86.6)). Patients in both cohorts with hypertension were predominantly >50 years old and female. Patients with hypertension were frequently diagnosed with obesity, heart disease, dyslipidaemia and diabetes. Compared with patients without hypertension, patients with hypertension in the COVID-19 diagnosed cohort had more hospitalisations (ranging from 1.3% (95% CI 0.4 to 2.2) to 41.1% (95% CI 39.5 to 42.7) vs from 1.4% (95% CI 0.9 to 1.9) to 15.9% (95% CI 14.9 to 16.9)) and increased mortality (ranging from 0.3% (95% CI 0.1 to 0.5) to 18.5% (95% CI 15.7 to 21.3) vs from 0.2% (95% CI 0.2 to 0.2) to 11.8% (95% CI 10.8 to 12.8)). Patients in the COVID-19 hospitalised cohort with hypertension were more likely to have acute respiratory distress syndrome (ranging from 0.1% (95% CI 0.0 to 0.2) to 65.6% (95% CI 62.5 to 68.7) vs from 0.1% (95% CI 0.0 to 0.2) to 54.7% (95% CI 50.5 to 58.9)), arrhythmia (ranging from 0.5% (95% CI 0.3 to 0.7) to 45.8% (95% CI 42.6 to 49.0) vs from 0.4% (95% CI 0.3 to 0.5) to 36.8% (95% CI 32.7 to 40.9)) and increased mortality (ranging from 1.8% (95% CI 0.4 to 3.2) to 25.1% (95% CI 23.0 to 27.2) vs from 0.7% (95% CI 0.5 to 0.9) to 10.9% (95% CI 10.4 to 11.4)) than patients without hypertension. Conclusions: COVID-19 patients with hypertension were more likely to suffer severe outcomes, hospitalisations and deaths compared with those without hypertension., This work was supported by several funders as follows: the European Health Data and Evidence Network received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement number 806968. The JU received support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. This research received partial support from the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), US National Institutes of Health (R01 LM006910), US Department of Veterans Affairs, the Health Department from the Generalitat de Catalunya with a grant for research projects on SARS-CoV-2 and COVID-19 disease organised by the Direcció General de Recerca i Innovació en Salut, Janssen Research and Development, TFS, IOMED and IQVIA. The University of Oxford received funding related to this work from the Bill and Melinda Gates Foundation (Investment ID INV-016201 and INV-019257). TFS received funding related to this work from the University of Oxford. This work was also supported with funding (resources and facilities) of the Department of Veterans Affairs (VA) Informatics and Computing Infrastructure (VINCI) (VA HSR RES 13-457).
RUC. Repositorio da Universidade da Coruña
Publication Contribución de congreso (ConferenceOutput)

Discovery of Biomedical Databases Through Semantic Questioning

  • Pereira, Arnaldo
  • Almeida, João Rafael
  • Lopes, Rui Pedro
  • Pazos, A.
  • Oliveira, José Luís
Included in Volume 294: Challenges of Trustable AI and Added-Value on Health from Series Studies in Health Technology and Informatics that includes the proceedings of the 32nd Medical Informatics Europe Conference (MIE2022), organized by the European Federation for Medical Informatics (EFMI) and held from 27 - 30 May 2022 in Nice, France., [Abstract]: Many clinical studies are greatly dependent on an efficient identification of relevant datasets. This selection can be performed in existing health data catalogues, by searching for available metadata. The search process can be optimised through questioning-answering interfaces, to help researchers explore the available data present. However, when searching the distinct catalogues the lack of metadata harmonisation imposes a few bottlenecks. This paper presents a methodology to allow semantic search over several biomedical database catalogues, by extracting the information using a shared domain knowledge. The resulting pipeline allows the converted data to be published as FAIR endpoints, and it provides an end-user interface that accepts natural language questions., This work has received support from the EU/EFPIA Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 806968. AP and JRA are funded by the FCT - Foundation for Science and Technology (national funds) under the grants PD/BD/142877/2018 and SFRH/BD/147837/2019 respectively., Portugal. Fundação para a Ciência e a Tecnologia; PD/BD/142878/2018, Portugal. Fundação para a Ciência e a Tecnologia; SFRH/BD/147837/2019
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

A Recommender System to Help Refining Clinical Research Studies

  • Almeida, João Rafael
  • Silva, João Figueira
  • Matos, Sergio
  • Pazos, A.
  • Oliveira, José Luís
[Abstract] The process of refining the research question in a medical study depends greatly on the current background of the investigated subject. The information found in prior works can directly impact several stages of the study, namely the cohort definition stage. Besides previous published methods, researchers could also leverage on other materials, such as the output of cohort selection tools, to enrich and to accelerate their own work. However, this kind of information is not always captured by search engines. In this paper, we present a methodology, based on a combination of content-based retrieval and text annotation techniques, to identify relevant scientific publications related to a research question and to the selected data sources., This work has received support from the EU/EFPIA Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 806968. JFS and JRA are funded by the FCT - Foundation for Science and Technology (national funds) under the grants PD/BD/142878/2018 and SFRH/BD/147837/2019 respectively., Portugal. Fundação para a Ciência e a Tecnologia; PD/BD/142878/2018, Portugal. Fundação para a Ciência e a Tecnologia; SFRH/BD/147837/2019
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

A federated authentication schema among multiple identity providers

  • Almeida, João Rafael
  • Zúquete, André
  • Pazos, A.
  • Oliveira, José Luís
[Abstract]: Single Sign-On (SSO) methods are the primary solution to authenticate users across multiple web systems. These mechanisms streamline the authentication procedure by avoiding duplicate developments of authentication modules for each application. Besides, these mechanisms also provide convenience to the end-user by keeping the user authenticated when switching between different contexts. To ensure this cross-application authentication, SSO relies on an Identity Provider (IdP), which is commonly set up and managed by each institution that needs to enforce SSO internally. However, the solution is not so straightforward when several institutions need to cooperate in a unique ecosystem. This could be tackled by centralizing the authentication mechanisms in one of the involved entities, a solution raising responsibilities that may be difficult for peers to accept. Moreover, this solution is not appropriate for dynamic groups, where peers may join or leave frequently. In this paper, we propose an architecture that uses a trusted third-party service to authenticate multiple entities, ensuring the isolation of the user's attributes between this service and the institutional SSO systems. This architecture was validated in the EHDEN Portal, which includes web tools and services of this European health project, to establish a Federated Authentication schema., JRA is funded by the National Science Foundation (FCT), under the grant SFRH/BD/147837/2019. The EHDEN project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 806968 (supported by the European Union and EFPIA)., Portugal. Foundation for Science and Technology; SFRH/BD/147837/2019
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

The natural history of symptomatic COVID-19 during the first wave in Catalonia

  • Burn, Edward
  • Tebé, Cristian
  • Fernández Bertolin, Sergio
  • Aragon, Maria
  • Recalde, Martina
  • Roel, Elena
  • Prats Uribe, Albert
  • Prieto Alhambra, Daniel
  • Duarte Salles, Talita
The natural history of coronavirus disease 2019 (COVID-19) has yet to be fully described. Here, we use patient-level data from the Information System for Research in Primary Care (SIDIAP) to summarise COVID-19 outcomes in Catalonia, Spain. We included 5,586,521 individuals from the general population. Of these, 102,002 had an outpatient diagnosis of COVID-19, 16,901 were hospitalised with COVID-19, and 5273 died after either being diagnosed or hospitalised with COVID-19 between 1st March and 6th May 2020. Older age, being male, and having comorbidities were all generally associated with worse outcomes. These findings demonstrate the continued need to protect those at high risk of poor outcomes, particularly older people, from COVID-19 and provide appropriate care for those who develop symptomatic disease. While risks of hospitalisation and death were lower for younger populations, there is a need to limit their role in community transmission.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The natural history of symptomatic COVID-19 during the first wave in Catalonia

  • Burn, Edward
  • Tebé, Cristian
  • Fernández Bertolin, Sergio
  • Aragon, Maria
  • Recalde, Martina
  • Roel, Elena
  • Prats Uribe, Albert
  • Prieto Alhambra, Daniel
  • Duarte Salles, Talita
The natural history of coronavirus disease 2019 (COVID-19) has yet to be fully described. Here, we use patient-level data from the Information System for Research in Primary Care (SIDIAP) to summarise COVID-19 outcomes in Catalonia, Spain. We included 5,586,521 individuals from the general population. Of these, 102,002 had an outpatient diagnosis of COVID-19, 16,901 were hospitalised with COVID-19, and 5273 died after either being diagnosed or hospitalised with COVID-19 between 1st March and 6th May 2020. Older age, being male, and having comorbidities were all generally associated with worse outcomes. These findings demonstrate the continued need to protect those at high risk of poor outcomes, particularly older people, from COVID-19 and provide appropriate care for those who develop symptomatic disease. While risks of hospitalisation and death were lower for younger populations, there is a need to limit their role in community transmission.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Characteristics and outcomes of patients with COVID-19 with and without prevalent hypertension: a multinational cohort study

  • Reyes, Carlen
  • Sorli Redó, M. Luisa
  • López Montesinos, Inmaculada
  • Duarte Salles, Talita, 1985-
Objective: To characterise patients with and without prevalent hypertension and COVID-19 and to assess adverse outcomes in both inpatients and outpatients. Design and setting: This is a retrospective cohort study using 15 healthcare databases (primary and secondary electronic healthcare records, insurance and national claims data) from the USA, Europe and South Korea, standardised to the Observational Medical Outcomes Partnership common data model. Data were gathered from 1 March to 31 October 2020. Participants: Two non-mutually exclusive cohorts were defined: (1) individuals diagnosed with COVID-19 (diagnosed cohort) and (2) individuals hospitalised with COVID-19 (hospitalised cohort), and stratified by hypertension status. Follow-up was from COVID-19 diagnosis/hospitalisation to death, end of the study period or 30 days. Outcomes: Demographics, comorbidities and 30-day outcomes (hospitalisation and death for the 'diagnosed' cohort and adverse events and death for the 'hospitalised' cohort) were reported. Results: We identified 2 851 035 diagnosed and 563 708 hospitalised patients with COVID-19. Hypertension was more prevalent in the latter (ranging across databases from 17.4% (95% CI 17.2 to 17.6) to 61.4% (95% CI 61.0 to 61.8) and from 25.6% (95% CI 24.6 to 26.6) to 85.9% (95% CI 85.2 to 86.6)). Patients in both cohorts with hypertension were predominantly >50 years old and female. Patients with hypertension were frequently diagnosed with obesity, heart disease, dyslipidaemia and diabetes. Compared with patients without hypertension, patients with hypertension in the COVID-19 diagnosed cohort had more hospitalisations (ranging from 1.3% (95% CI 0.4 to 2.2) to 41.1% (95% CI 39.5 to 42.7) vs from 1.4% (95% CI 0.9 to 1.9) to 15.9% (95% CI 14.9 to 16.9)) and increased mortality (ranging from 0.3% (95% CI 0.1 to 0.5) to 18.5% (95% CI 15.7 to 21.3) vs from 0.2% (95% CI 0.2 to 0.2) to 11.8% (95% CI 10.8 to 12.8)). Patients in the COVID-19 hospitalised cohort with hypertension were more likely to have acute respiratory distress syndrome (ranging from 0.1% (95% CI 0.0 to 0.2) to 65.6% (95% CI 62.5 to 68.7) vs from 0.1% (95% CI 0.0 to 0.2) to 54.7% (95% CI 50.5 to 58.9)), arrhythmia (ranging from 0.5% (95% CI 0.3 to 0.7) to 45.8% (95% CI 42.6 to 49.0) vs from 0.4% (95% CI 0.3 to 0.5) to 36.8% (95% CI 32.7 to 40.9)) and increased mortality (ranging from 1.8% (95% CI 0.4 to 3.2) to 25.1% (95% CI 23.0 to 27.2) vs from 0.7% (95% CI 0.5 to 0.9) to 10.9% (95% CI 10.4 to 11.4)) than patients without hypertension. Conclusions: COVID-19 patients with hypertension were more likely to suffer severe outcomes, hospitalisations and deaths compared with those without hypertension., This work was supported by several funders as follows: the European Health Data and Evidence Network received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement number 806968. The JU received support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. This research received partial support from the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), US National Institutes of Health (R01 LM006910), US Department of Veterans Affairs, the Health Department from the Generalitat de Catalunya with a grant for research projects on SARS-CoV-2 and COVID-19 disease organised by the Direcció General de Recerca i Innovació en Salut, Janssen Research and Development, TFS, IOMED and IQVIA. The University of Oxford received funding related to this work from the Bill and Melinda Gates Foundation (Investment ID INV-016201 and INV-019257). TFS received funding related to this work from the University of Oxford. This work was also supported with funding (resources and facilities) of the Department of Veterans Affairs (VA) Informatics and Computing Infrastructure (VINCI) (VA HSR RES 13-457).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Phenotype algorithms for the identification and characterization of vaccine-induced thrombotic thrombocytopenia in real world data: a multinational network cohort study

  • Shoaibi, Azza
  • Mayer, Miguel Ángel, 1960-
  • Ramírez Anguita, Juan Manuel
  • Ryan, Patrick B.
Introduction: vaccine-induced thrombotic thrombocytopenia (VITT) has been identified as a rare but serious adverse event associated with coronavirus disease 2019 (COVID-19) vaccines. Objectives: in this study, we explored the pre-pandemic co-occurrence of thrombosis with thrombocytopenia (TWT) using 17 observational health data sources across the world. We applied multiple TWT definitions, estimated the background rate of TWT, characterized TWT patients, and explored the makeup of thrombosis types among TWT patients. Methods: we conducted an international network retrospective cohort study using electronic health records and insurance claims data, estimating background rates of TWT amongst persons observed from 2017 to 2019. Following the principles of existing VITT clinical definitions, TWT was defined as patients with a diagnosis of embolic or thrombotic arterial or venous events and a diagnosis or measurement of thrombocytopenia within 7 days. Six TWT phenotypes were considered, which varied in the approach taken in defining thrombosis and thrombocytopenia in real world data. Results: overall TWT incidence rates ranged from 1.62 to 150.65 per 100,000 person-years. Substantial heterogeneity exists across data sources and by age, sex, and alternative TWT phenotypes. TWT patients were likely to be men of older age with various comorbidities. Among the thrombosis types, arterial thrombotic events were the most common. Conclusion: our findings suggest that identifying VITT in observational data presents a substantial challenge, as implementing VITT case definitions based on the co-occurrence of TWT results in large and heterogeneous incidence rate and in a cohort of patints with baseline characteristics that are inconsistent with the VITT cases reported to date., This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA. Funders had no role in the conceptualization, design, data collection, analysis, decision to publish, or preparation of the manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Evaluating the impact of alternative phenotype definitions on incidence rates across a global data network

  • Makadia, Rupa
  • Shoaibi, Azza
  • Rao, Gowtham A.
  • Ostropolets, Anna
  • Rijnbeek, Peter
  • Voss, Erica A.
  • Duarte Salles, Talita, 1985-
  • Ramírez Anguita, Juan Manuel
  • Mayer, Miguel Ángel, 1960-
  • Maljkovic, Filip
  • Denaxas, Spiros
  • Nyberg, Fredrik
  • Papez, Vaclav
  • Sena, Anthony G.
  • Alshammari, Thamir M.
  • Lai, Lana Y. H.
  • Haynes, Kevin
  • Suchard, Marc A.
  • Hripcsak, George
  • Ryan, Patrick B.
Objective: Developing accurate phenotype definitions is critical in obtaining reliable and reproducible background rates in safety research. This study aims to illustrate the differences in background incidence rates by comparing definitions for a given outcome. Materials and methods: We used 16 data sources to systematically generate and evaluate outcomes for 13 adverse events and their overall background rates. We examined the effect of different modifications (inpatient setting, standardization of code set, and code set changes) to the computable phenotype on background incidence rates. Results: Rate ratios (RRs) of the incidence rates from each computable phenotype definition varied across outcomes, with inpatient restriction showing the highest variation from 1 to 11.93. Standardization of code set RRs ranges from 1 to 1.64, and code set changes range from 1 to 2.52. Discussion: The modification that has the highest impact is requiring inpatient place of service, leading to at least a 2-fold higher incidence rate in the base definition. Standardization showed almost no change when using source code variations. The strength of the effect in the inpatient restriction is highly dependent on the outcome. Changing definitions from broad to narrow showed the most variability by age/gender/database across phenotypes and less than a 2-fold increase in rate compared to the base definition. Conclusion: Characterization of outcomes across a network of databases yields insights into sensitivity and specificity trade-offs when definitions are altered. Outcomes should be thoroughly evaluated prior to use for background rates for their plausibility for use across a global network., This research was funded by the European Union’s Horizon 2020 research and innovation programme and EFPIA, European Health Data & Evidence Network (EHDEN) grant agreement number 806968. T.D.-S. acknowledges receiving financial support from the Instituto de Salud Carlos III (ISCIII; Miguel Servet 2021: CP21/00023).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Incidence of post-acute COVID-19 symptoms across healthcare settings in seven countries: an international retrospective cohort study using routinely-collected data

  • Xie, Junqing
  • Mayer, Miguel Ángel, 1960-
  • Ramírez Anguita, Juan Manuel
  • Jödicke, Annika M.
Background: The World Health Organisation (WHO) has identified a range of symptomatic manifestations to aid in the clinical diagnosis of post-COVID conditions, herein referred to as post-acute COVID-19 symptoms. We conducted an international network cohort study to estimate the burden of these symptoms in North American, European, and Asian populations. Methods: A federated analysis was conducted including 10 databases from the United Kingdom, Netherlands, Norway, Estonia, Spain, France, South Korea, and the United States, between September 1st 2020 and latest data availability (which varied from December 31st 2021 to February 28th 2023), covering primary and secondary care, nationwide registries, and claims data, all mapped to the Observational Medical Outcomes Partnership Common Data Model (OMOP CDM). We defined two cohorts for the main analyses: a SARS-CoV-2 infection cohort [positive polymerase chain reaction (PCR) or rapid lateral flow test (LFT) result or clinical COVID-19 diagnosis] and a general population cohort. Individuals with less than 365 days of prior history or 120 days of follow-up were excluded. We estimated incidence rates (IRs) of the 25 WHO-proposed post-acute COVID-19 symptoms, considering symptoms that occurred ≥90 and ≤365 days after index date, excluding individuals with the respective symptoms 180 days prior to the index event. Stratified analyses were conducted by age and sex. Incidence rate ratios (IRRs) were calculated comparing rates in the infected cohort versus the general population. Results from the different databases were combined using random-effects meta-analyses. Findings: 3,019,408 individuals were included in the infection cohort. 1,585,160 of them were female and 1,434,248 of them male. 929,351,505 individuals were included in the general population group. 461,195,036 of them were female and 466,022,004 of them male. The 1-year IR of any post-acute COVID-19 symptom in the COVID-19 infection cohort varied significantly across databases, from 4.4 (95% CI 3.8-5.1) per 100 person-years to 103.9 (95% CI 103.2-104.7). The five most common symptoms were joint pain (from 1.6 (95% CI 1.3-1.9) to 14.3 (95% CI 14.1-14.6)), abdominal pain (from 0.3 (95% CI 0.1-0.5) to 9.9 (95% CI 9.7-10.1)), gastrointestinal issues (from 0.6 (95% CI 0.4-0.9) to 13.3 (95% CI 13.1-13.6)), cough (from 0.3 (95% CI 0.2-0.5) to 9.1 (95% CI 8.9-9.3)), and anxiety (from 0.8 (95% CI 0.6-1.2) to 11.4 (95% CI 11.2-11.6)); whereas muscle spasms (from 0.01 (95% CI 0.008-0.2) to 1.7 (95% CI 1.6-1.8)), pins and needles (from 0.05 (95% CI 0.03-0.0.9) to 1.5 (95% CI 1.4-1.6)), memory issues (from 0.03 (95% CI 0.02-0.06) to 0.8 (95% CI 0.7-0.8)), cognitive dysfunction (from 0.007 (95% CI 0.004-0.01) to 0.6 (95% CI 0.4-0.8)), and altered smell and/or taste (from 0.04 (95% CI 0.03-0.04) to 0.7 (95% CI 0.6-0.8)) were least common. Incidence rates of any post-acute COVID-19 symptoms generally increased with age, with certain symptoms peaking in middle-aged adults (anxiety, depressive disorders, headache, altered smell and taste) and others in pre-school children (gastrointestinal issues and cough). Females had higher incidence rates for most symptoms. Based on the random-effects model, the infected cohort had a higher incidence of any post-acute COVID-19 symptom than the general population, with a meta-analytic incidence rate ratio (meta-IRR) of 1.4 (1-2). A similar pattern was seen for all individual symptoms. The highest meta-IRRs were depressive disorder, 2.6 (1.7-3.9); anxiety, 2.3 (1.4-3.8); allergy, 2.1 (1.7-2.8) and sleep disorders, 2.1 (1.5-2.6). The meta-IRR for altered smell and/or taste was 1.9 (1.3-2.8). Interpretation: Post-acute COVID-19 symptoms, as listed by the WHO, were commonly observed following COVID-19 infection. However, even after standardising research methods, there was significant heterogeneity in the incidence rates from different healthcare settings and geographical locations. This is the first international study of the epidemiology of post-acute COVID-19 symptoms using the WHO-listed symptoms. Its findings contibute to understand the epidemiology of this condition from a multinational approach. Limitations of this study include the lack of consensus of the post-acute COVID-19 definition, as well as the difficulty to capture the impact on daily life of the post-acute COVID-19 symptoms in the available datasets. Funding: This work has been funded by the European Health Data Evidence Network (EHDEN) through an Evidence Generation Fund Grant and by the National Institute for Health and Care Research (NIHR) Oxford Biomedical Research Centre (BRC)., This work has been funded by the European Health Data Evidence Network (EHDEN) through an Evidence Generation Fund Grant. EHDEN has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 806968. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.
Dipòsit Digital de Documents de la UAB
Publication

Characteristics and outcomes of 627 044 COVID-19 patients living with and without obesity in the United States, Spain, and the United Kingdom

  • Recalde, Martina|||0000-0003-2256-618X
  • Roel Herranz, Elena|||0000-0002-1964-3546
  • Pistillo, Andrea|||0000-0002-4467-0220
  • Sena, Anthony G.|||0000-0001-8630-5347
  • Prats-Uribe, Albert|||0000-0003-1202-9153
  • Ahmed, Waheed-Ul-Rahman|||0000-0003-0880-0355
  • Alghoul, Heba|||0000-0001-8234-5843
  • Alshammari, Thamir|||0000-0002-5630-2468
  • Alser, Osaid|||0000-0001-6743-803X
  • Areia, Carlos|||0000-0002-4668-7069
  • Burn, Edward|||0000-0002-9286-1128
  • Casajust, Paula|||0000-0003-2733-5436
  • Dawoud, Dalia
  • Duvall, Scott L.
  • Falconer, Thomas|||0000-0001-6904-1394
  • Fernández-Bertolín, Sergio|||0000-0002-0029-6564
  • Golozar, Asieh|||0000-0002-4243-155X
  • Gong, Mengchun
  • Lai, Lana Yin Hui
  • Lane, Jennifer C.E.
  • Lynch, Kristine E.
  • Matheny, Michael E.
  • Mehta, Paras P.
  • Morales, Daniel R.
  • Natarjan, Karthik
  • Nyberg, Fredrik|||0000-0003-0892-5668
  • Posada, Jose D.
  • Reich, Christian G.|||0000-0002-3641-055X
  • Rijnbeek, Peter|||0000-0003-0621-1979
  • Schilling, Lisa M.|||0000-0002-6878-189X
  • Shah, Karishma
  • Shah, Nigam H.
  • Subbian, Vignesh
  • Zhang, Lin|||0000-0003-1998-0611
  • Zhu, Hong
  • Ryan, Patrick
  • Prieto-Alhambra, Daniel|||0000-0002-3950-6346
  • Kostka, Kristin|||0000-0003-2595-8736
  • Duarte Salles, Talita|||0000-0002-8274-0357
A detailed characterization of patients with COVID-19 living with obesity has not yet been undertaken. We aimed to describe and compare the demographics, medical conditions, and outcomes of COVID-19 patients living with obesity (PLWO) to those of patients living without obesity. We conducted a cohort study based on outpatient/inpatient care and claims data from January to June 2020 from Spain, the UK, and the US. We used six databases standardized to the OMOP common data model. We defined two non-mutually exclusive cohorts of patients diagnosed and/or hospitalized with COVID-19; patients were followed from index date to 30 days or death. We report the frequency of demographics, prior medical conditions, and 30-days outcomes (hospitalization, events, and death) by obesity status. We included 627 044 (Spain: 122 058, UK: 2336, and US: 502 650) diagnosed and 160 013 (Spain: 18 197, US: 141 816) hospitalized patients with COVID-19. The prevalence of obesity was higher among patients hospitalized (39.9%, 95%CI: 39.8-40.0) than among those diagnosed with COVID-19 (33.1%; 95%CI: 33.0-33.2). In both cohorts, PLWO were more often female. Hospitalized PLWO were younger than patients without obesity. Overall, COVID-19 PLWO were more likely to have prior medical conditions, present with cardiovascular and respiratory events during hospitalization, or require intensive services compared to COVID-19 patients without obesity. We show that PLWO differ from patients without obesity in a wide range of medical conditions and present with more severe forms of COVID-19, with higher hospitalization rates and intensive services requirements. These findings can help guiding preventive strategies of COVID-19 infection and complications and generating hypotheses for causal inference studies.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Characteristics, outcomes, and mortality amongst 133,589 patients with prevalent autoimmune diseases diagnosed with, and 48,418 hospitalised for COVID-19, a multinational distributed network cohort analysis

  • Tan, Eng Hooi
  • Sena, Anthony G.|||0000-0001-8630-5347
  • Prats-Uribe, Albert|||0000-0003-1202-9153
  • You, Seng Chan
  • Ahmed, Waheed-Ul-Rahman|||0000-0003-0880-0355
  • Kostka, Kristin|||0000-0003-2595-8736
  • Reich, Christian
  • Duvall, Scott L.
  • Lynch, Kristine E.
  • Matheny, Michael E.
  • Duarte Salles, Talita|||0000-0002-8274-0357
  • Bertolin, Sergio Fernandez
  • Hripcsak, George|||0000-0003-2664-7614
  • Natarajan, Karthik|||0000-0002-9066-9431
  • Falconer, Thomas|||0000-0001-6904-1394
  • Spotnitz, Matthew
  • Ostropolets, Anna
  • Blacketer, Clair
  • Alshammari, Thamir|||0000-0002-5630-2468
  • Alghoul, Heba|||0000-0001-8234-5843
  • Alser, Osaid|||0000-0001-6743-803X
  • Lane, Jennifer C.E.
  • Dawoud, Dalia
  • Shah, Karishma
  • Yang, Yue
  • Zhang, Lin|||0000-0003-1998-0611
  • Areia, Carlos|||0000-0002-4668-7069
  • Golozar, Asieh|||0000-0002-4243-155X
  • Relcade, Martina
  • Casajust, Paula|||0000-0003-2733-5436
  • Jonnagaddala, Jitendra
  • Subbian, Vignesh
  • Vizcaya, David
  • Lai, Lana Y. H.
  • Nyberg, Fredrik|||0000-0003-0892-5668
  • Morales, Daniel R.
  • Posada, Jose D.
  • Shah, Nigam H.
  • Gong, Mengchun
  • Vivekanantham, Arani
  • Abend, Aaron
  • Minty, Evan P.
  • Suchard, Marc|||0000-0001-9818-479X
  • Rijnbeek, Peter|||0000-0003-0621-1979
  • Ryan, Patrick B.|||0000-0002-9727-2138
  • Prieto-Alhambra, Daniel|||0000-0002-3950-6346
Patients with autoimmune diseases were advised to shield to avoid COVID-19, but information on their prognosis is lacking. We characterised 30-day outcomes and mortality after hospitalisation with COVID-19 among patients with prevalent autoimmune diseases, and compared outcomes after hospital admissions among similar patients with seasonal influenza. Multinational network cohort study Electronic health records data from Columbia University Irving Medical Center (CUIMC) (NYC, United States [US]), Optum [US], Department of Veterans Affairs (VA) (US), Information System for Research in Primary Care-Hospitalisation Linked Data (SIDIAP-H) (Spain), and claims data from IQVIA Open Claims (US) and Health Insurance and Review Assessment (HIRA) (South Korea). All patients with prevalent autoimmune diseases, diagnosed and/or hospitalised between January and June 2020 with COVID-19, and similar patients hospitalised with influenza in 2017-2018 were included. 30-day complications during hospitalisation and death We studied 133,589 patients diagnosed and 48,418 hospitalised with COVID-19 with prevalent autoimmune diseases. The majority of participants were female (60.5% to 65.9%) and aged ≥50 years. The most prevalent autoimmune conditions were psoriasis (3.5 to 32.5%), rheumatoid arthritis (3.9 to 18.9%), and vasculitis (3.3 to 17.6%). Amongst hospitalised patients, Type 1 diabetes was the most common autoimmune condition (4.8% to 7.5%) in US databases, rheumatoid arthritis in HIRA (18.9%), and psoriasis in SIDIAP-H (26.4%). Compared to 70,660 hospitalised with influenza, those admitted with COVID-19 had more respiratory complications including pneumonia and acute respiratory distress syndrome, and higher 30-day mortality (2.2% to 4.3% versus 6.3% to 24.6%). Patients with autoimmune diseases had high rates of respiratory complications and 30-day mortality following a hospitalization with COVID-19. Compared to influenza, COVID-19 is a more severe disease, leading to more complications and higher mortality. Future studies should investigate predictors of poor outcomes in COVID-19 patients with autoimmune diseases.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Use of dialysis, tracheostomy, and extracorporeal membrane oxygenation among 842,928 patients hospitalized with COVID-19 in the United States

  • Burn, Edward|||0000-0002-9286-1128
  • Sena, Anthony G.|||0000-0001-8630-5347
  • Prats-Uribe, Albert|||0000-0003-1202-9153
  • Spotnitz, Matthew
  • DuVall, Scott
  • Lynch, Kristine E.
  • Matheny, Michael E.
  • Nyberg, Fredrik|||0000-0003-0892-5668
  • Ahmed, Waheed-Ul-Rahman|||0000-0003-0880-0355
  • Alser, Osaid|||0000-0001-6743-803X
  • Alghoul, Heba|||0000-0001-8234-5843
  • Alshammari, Thamir|||0000-0002-5630-2468
  • Zhang, Lin|||0000-0003-1998-0611
  • Casajust, Paula|||0000-0003-2733-5436
  • Areia, Carlos|||0000-0002-4668-7069
  • Shah, Karishma
  • Reich, Christian
  • Blacketer, Clair
  • Andryc, Alan|||0000-0002-2663-2298
  • Fortin, Stephen
  • Natarajan, Karthik|||0000-0002-9066-9431
  • Gong, Mengchun
  • Golozar, Asieh|||0000-0002-4243-155X
  • Morales, Daniel
  • Rijnbeek, Peter|||0000-0003-0621-1979
  • Subbian, Vignesh
  • Roel Herranz, Elena|||0000-0002-1964-3546
  • Recalde, Martina|||0000-0003-2256-618X
  • Lane, Jennifer C.E.
  • Vizcaya, David
  • Posada, Jose D.
  • Shah, Nigam H.
  • Jonnagaddala, Jitendra
  • Lai, Lana Yin Hui
  • Avilés-Jurado, Francesc Xavier|||0000-0001-5560-8097
  • Hripcsak, George|||0000-0003-2664-7614
  • Suchard, Marc|||0000-0001-9818-479X
  • Ranzani, Otavio|||0000-0002-4677-6862
  • Ryan, Patrick
  • Prieto-Alhambra, Daniel|||0000-0002-3950-6346
  • Kostka, Kristin|||0000-0003-2595-8736
  • Duarte Salles, Talita|||0000-0002-8274-0357
To estimate the proportion of patients hospitalized with COVID-19 who undergo dialysis, tracheostomy, and extracorporeal membrane oxygenation (ECMO). A network cohort study. Seven databases from the United States containing routinely-collected patient data: HealthVerity, Premier, IQVIA Hospital CDM, IQVIA Open Claims, Optum EHR, Optum SES, and VA-OMOP. Patients hospitalized with a clinical diagnosis or a positive test result for COVID-19. Dialysis, tracheostomy, and ECMO. 842,928 patients hospitalized with COVID-19 were included (22,887 from HealthVerity, 77,853 from IQVIA Hospital CDM, 533,997 from IQVIA Open Claims, 36,717 from Optum EHR, 4,336 from OPTUM SES, 156,187 from Premier, and 10,951 from VA-OMOP). Across the six databases, 35,192 (4.17% [95% CI: 4.13% to 4.22%]) patients received dialysis, 6,950 (0.82% [0.81% to 0.84%]) had a tracheostomy, and 1,568 (0.19% [95% CI: 0.18% to 0.20%]) patients underwent ECMO over the 30 days following hospitalization. Use of ECMO was more common among patients who were younger, male, and with fewer comorbidities. Tracheostomy was broadly used for a similar proportion of patients regardless of age, sex, or comorbidity. While dialysis was generally used for a similar proportion among younger and older patients, it was more frequent among male patients and among those with chronic kidney disease. Use of dialysis among those hospitalized with COVID-19 is high at around 4%. Although less than one percent of patients undergo tracheostomy and ECMO, the absolute numbers of patients who have undergone these interventions is substantial.